Christine Zedelmayer, Sr. Vice President and Chief Operating Officer of Equillium Inc (EQ, Financial), executed a sale of 15,000 shares of the company on October 28, 2024. The transaction was filed on October 31, 2024, as reported in the SEC Filing. Following this transaction, the insider now owns 135,246 shares of Equillium Inc.
Equillium Inc focuses on the development of products for autoimmune and inflammatory disorders. Their strategic approach targets critical biological pathways involved in a range of severe diseases.
Over the past year, the insider has sold a total of 15,000 shares and has not purchased any shares. This recent sale reflects a continuation of the insider's trading activities, aligning with the broader insider trading pattern at Equillium Inc. Over the last year, there have been no insider buys and five insider sells within the company.
Shares of Equillium Inc were priced at $1.25 on the day of the transaction. The company's market cap stands at approximately $48.886 million.
The valuation metrics for Equillium Inc include a price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. These indicators are essential for investors considering the stock's current valuation in relation to its earnings, sales, book value, and cash flow.
The GF Value is a proprietary measure used to determine the fair value of a stock, taking into account historical ratios, an internal adjustment factor, and future earnings projections.
This insider sale might be of interest to current and potential investors, as insider transactions can provide valuable insights into a company's internal dynamics and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
